Natalia Buza1, Dana M Roque, Alessandro D Santin. 1. From the Departments of Pathology (Dr Buza) and Obstetrics, Gynecology, and Reproductive Sciences (Drs Roque and Santin), Yale University School of Medicine, New Haven, Connecticut; and the Gynecologic Oncology Program, Yale Cancer Center, New Haven, Connecticut (Dr Santin).
Abstract
CONTEXT: In the era of targeted cancer therapy, there is growing interest in developing novel therapeutic strategies against endometrial carcinoma, especially its most biologically aggressive variant, serous adenocarcinoma. Several publications have demonstrated that a significant proportion of uterine serous carcinomas show HER2 overexpression and/or amplification, suggesting that HER2 may be a promising therapeutic target. Case reports have already shown clinical response to trastuzumab, a humanized monoclonal immunoglobulin (Ig) G1 antibody against HER2, and patients are currently being enrolled in a multi-institutional prospective randomized trial to evaluate the therapeutic efficacy of trastuzumab. OBJECTIVE: To review current data on HER2 testing and targeted therapy against HER2/neu in endometrial carcinoma. DATA SOURCES: Review of the literature and personal experience of the authors. CONCLUSIONS: Parallel to the clinical studies, there is a need to develop standardized criteria for HER2 testing in endometrial carcinoma that reflect the unique biological and pathogenetic features of these tumors and correlate with clinical response to therapy. This article presents a comprehensive review of the current state of HER2-based therapy and HER2 testing in endometrial carcinoma.
CONTEXT: In the era of targeted cancer therapy, there is growing interest in developing novel therapeutic strategies against endometrial carcinoma, especially its most biologically aggressive variant, serous adenocarcinoma. Several publications have demonstrated that a significant proportion of uterine serous carcinomas show HER2 overexpression and/or amplification, suggesting that HER2 may be a promising therapeutic target. Case reports have already shown clinical response to trastuzumab, a humanized monoclonal immunoglobulin (Ig) G1 antibody against HER2, and patients are currently being enrolled in a multi-institutional prospective randomized trial to evaluate the therapeutic efficacy of trastuzumab. OBJECTIVE: To review current data on HER2 testing and targeted therapy against HER2/neu in endometrial carcinoma. DATA SOURCES: Review of the literature and personal experience of the authors. CONCLUSIONS: Parallel to the clinical studies, there is a need to develop standardized criteria for HER2 testing in endometrial carcinoma that reflect the unique biological and pathogenetic features of these tumors and correlate with clinical response to therapy. This article presents a comprehensive review of the current state of HER2-based therapy and HER2 testing in endometrial carcinoma.
Authors: Jolijn W Groeneweg; Silvia F Hernandez; Virginia F Byron; Celeste M DiGloria; Hector Lopez; Vanessa Scialabba; Minji Kim; Ling Zhang; Darrell R Borger; Rosemary Tambouret; Rosemary Foster; Bo R Rueda; Whitfield B Growdon Journal: Clin Cancer Res Date: 2014-10-07 Impact factor: 12.531
Authors: Linshan Hu; Shan Liang; Hu Chen; Tao Lv; Junfeng Wu; Deshi Chen; Min Wu; Shengnan Sun; Haibo Zhang; Han You; Hongbin Ji; Yujun Zhang; Johann Bergholz; Zhi-Xiong Jim Xiao Journal: Proc Natl Acad Sci U S A Date: 2017-05-03 Impact factor: 11.205
Authors: Whitfield B Growdon; Jolijn Groeneweg; Virginia Byron; Celeste DiGloria; Darrell R Borger; Rosemary Tambouret; Rosemary Foster; Ahmed Chenna; Jeff Sperinde; John Winslow; Bo R Rueda Journal: Gynecol Oncol Date: 2015-01-17 Impact factor: 5.482
Authors: Sylwia M Łapińska-Szumczyk; Anna M Supernat; Hanna I Majewska; Jacek Gulczyński; Wojciech Biernat; Dariusz Wydra; Anna J Żaczek Journal: Int J Clin Exp Med Date: 2015-11-15
Authors: Carrie L Robinson; Beth T Harrison; Azra H Ligon; Fei Dong; Valeria Maffeis; Ursula Matulonis; Marisa R Nucci; David L Kolin Journal: Mod Pathol Date: 2020-10-19 Impact factor: 7.842
Authors: Amanda N Fader; Dana M Roque; Eric Siegel; Natalia Buza; Pei Hui; Osama Abdelghany; Setsuko Chambers; Angeles Alvarez Secord; Laura Havrilesky; David M O'Malley; Floor J Backes; Nicole Nevadunsky; Babak Edraki; Dirk Pikaart; William Lowery; Karim ElSahwi; Paul Celano; Stefania Bellone; Masoud Azodi; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Peter E Schwartz; Alessandro D Santin Journal: Clin Cancer Res Date: 2020-06-29 Impact factor: 12.531